RxDoctor Payments Data

Parminder Chawla, MD

Neurology · Leesburg, VANPI 1285605865

Payments from drug & device makers

$30,392in general payments, 2019–2025

Across 1,567 payments — averaging $19.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$3K
  • AbbVie$3K
  • Lilly USA, LLC$2K
  • UCB, Inc.$2K
  • Biogen$2K
  • Novartis$1K
  • plus $17K from 54 others

What the payments were for

  • Speaking & faculty fees$2821%
  • Food & beverage$29,63698%
  • Education$4752%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Teva Pharmaceuticals USA, Inc.226$3,470
AbbVie(2 entities)136$3,223
Lilly USA, LLC82$1,865
UCB, Inc.82$1,681
Biogen80$1,513
Novartis80$1,381
Acadia Pharmaceuticals Inc58$1,057
Lundbeck LLC46$1,023
Amgen(2 entities)46$982
Pfizer56$970
EMD Serono, Inc.44$847
Amneal Pharmaceuticals LLC43$846
Neurocrine Biosciences, Inc.30$668
Sunovion Pharmaceuticals Inc.37$664
Eisai Inc.37$639
SK Life Science, Inc.25$537
Neurelis, Inc.30$523
MDD US Operations, LLC19$485
Kyowa Kirin, Inc.25$430
AstraZeneca(2 entities)17$407
Adamas Pharmaceuticals, Inc.28$405
Harmony Biosciences LLC17$404
Supernus Pharmaceuticals, Inc.21$401
Sanofi19$392
Genentech USA, Inc.26$390
Acorda Therapeutics, Inc20$378
Bristol Myers Squibb18$348
Catalyst Pharmaceuticals, Inc.14$314
Avanir Pharmaceuticals, Inc.19$293
Sumitomo Pharma America, Inc.18$280
Impel Pharmaceuticals Inc.9$275
Upsher-smith Laboratories LLC13$258
Otsuka America Pharmaceutical, Inc.14$244
Vanda Pharmaceuticals Inc.10$243
Axsome Therapeutics, Inc.10$229
ANI Pharmaceuticals, Inc.10$219
Currax Pharmaceuticals LLC16$212
Biohaven Pharmaceutical Holding Company Ltd.15$205
Corium, LLC6$195
TG Therapeutics, Inc.3$190
Jazz Pharmaceuticals Inc.9$187
Tanabe Pharma America, Inc.7$158
Argenx US, Inc.5$113
Scilex Pharmaceuticals Inc.6$112
Novo Nordisk1$97
Arbor Pharmaceuticals, Inc.6$82
Life Molecular Imaging Ltd2$68
Alfasigma USA, Inc.3$58
E.r. Squibb & Sons, L.L.C.3$48
GE HealthCare2$47
Idorsia Pharmaceuticals US Inc2$43
Assertio Therapeutics, Inc.2$35
Globus Medical1$30
Kowa Pharmaceuticals America, Inc.2$30
C2n Diagnostics, LLC1$25
Grifols USA, LLC1$24
Collegium Pharmaceutical, Inc.1$24
Ultragenyx Pharmaceutical Inc.1$21
Biohaven Pharmaceuticals, Inc.1$18
Mallinckrodt Hospital Products Inc.1$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$30,392 in reported general payments places this provider in the 80th percentile of 474 neurology providers in Virginia.

See all neurology providers in Virginia

Medicare billing

Part B allowed, 2024
$251,995
Medicare patients
719
Services billed
2,428

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate23$123,406
IngrezzaValbenazine Tosylate13$105,259
RytaryCarbidopa/Levodopa40$75,454
QuliptaAtogepant49$62,918
Nurtec OdtRimegepant Sulfate33$53,157
RexultiBrexpiprazole29$42,432
UbrelvyUbrogepant29$40,399
GocovriAmantadine Hcl16$39,537
Memantine Hcl892$29,996
NourianzIstradefylline13$24,651
Ajovy AutoinjectorFremanezumab-Vfrm33$24,155
Rivastigmine121$24,026
Diflorasone Diacetate37$20,597
Emgality PenGalcanezumab-Gnlm21$18,730
FycompaPerampanel14$18,699

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$1,057$123,40623 claims
Neurocrine Biosciences, Inc.Ingrezza$668$105,25913 claims
AbbVieQulipta, Ubrelvy$3,223$103,31778 claims
Amneal Pharmaceuticals LLCRytary$846$75,45440 claims
PfizerNurtec Odt$970$53,15733 claims
Otsuka America Pharmaceutical, Inc.Rexulti$244$42,43229 claims
MDD US Operations, LLCGocovri$485$39,53716 claims
Kyowa Kirin, Inc.Nourianz$430$24,65113 claims
Eisai Inc.Fycompa$639$18,69914 claims
UCB, Inc.Briviact$1,681$16,96012 claims
Corium, LLCAdlarity$195$5,83611 claims
Upsher-smith Laboratories LLCTopiramate$258$1,52792 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 474 neurology providers in Virginia.

Other neurology in Leesburg

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →